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Background: To assess the distribution of costs associatedwith Cardiology Unit hospitalization
due to acute heart failure (AHF) and evaluate, from the perspective of the healthcare payer,
the heterogeneity of resources use according to AHF etiology in patients from 2005 to 2009.
Methods: The type and etiology of AHF was determined upon hospital admission. The cost of
in-patient care was based on the individual hospital account of each patient (1759 patients in
total; 58.7% male; mean age 71 years).
Results: The median hospital stay was 7 days and the mean total cost of in-patient care was
h3364. A Coronary Care Unit (CCU) stay was recorded in 67.4% patients (median 3 days).
Significantly higher costs were found in de-novo AHF patients (mean h3678) with a greater
need for CCU care, a longer stay in the CCU and a greater need for intervention (particularly
that of percutaneous coronary intervention (PCI)), than in patients with acute decompensa-
tion of chronic heart failure (mean cost h2878; po0.001). Acute coronary syndrome was a
major precipitating factor, with the highest costs (h4429) resulting from having received PCI
(63.3% of patients) and CCU admission (91.7% of patients). Variations in length of stay
according to AHF etiology were minor (median, 6–8 days). In-hospital mortality was 15.0%.ch Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All rights reserved.
Internal Cardiology Medicine, University Hospital Brno, Jihlavska´ 20, Brno 625 00,
Parenica).
is work.
.
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 7 – e 1 4e8Conclusions: Hospitalization costs as they relate to AHF are high, particularly in new-onset
AHF patients. The heterogeneity of resources use is largely a reflection of interventions
undertaken, particularly if revascularization or anti-arrhythmic therapy is provided.
& 2012 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All
rights reserved.
.1. BackgroundAccording to the European Society of Cardiology, acute heart
failure (AHF) is defined as the ‘‘rapid onset of symptoms and
signs secondary to abnormal cardiac function’’ [1]. Cardiac
dysfunction associated with AHF can be related to anything
from systolic or diastolic dysfunction, to abnormalities in
cardiac rhythm, or preload/afterload mismatch. AHF may
present as acute de-novo (the new onset of AHF in patients
without previously documented cardiac dysfunction) or as
acute decompensation of previously diagnosed chronic heart
failure (ADCHF). The severity AHF ranges from the sudden
appearance of mild dyspnea to cardiogenic shock. The major
therapeutic aim is to control symptoms and stabilize hemo-
dynamics. Prognosis is improved by immediate elimination
of the cause of the acute condition (ischemia is treated by
surgical or interventional revascularization; valvular disease
by surgery; arrhythmias by anti-arrhythmic drugs or defibril-
lation), or the application of pharmacotherapy to prevent
disease progression and future acute decompensation.
AHF is associated with a poor prognosis. Although AHF is a
life-threatening disease and a high burden on healthcare
systems, there is relatively limited data describing the epide-
miology, treatment, prognosis and resource utilization in AHF
patients in European countries. The EuroHeart Failure Survey
(EHFS) evaluated 11,327 patients in 24 countries. The study
population involved patients with AHF and CHF who were
primarily hospitalized for other reasons (40% of admissions
were due to heart failure), as well as those with only possible
heart failure (17%) [2,3]. HF patient characteristics, presenta-
tion, treatment and outcome were assessed by the Euro Heart
Failure Survey II (EHFS II). This involved 3580 patients from 30
countries and was in accordance with the European Society of
Cardiology’s published guidelines for the diagnosis and treat-
ment of AHF [1,4]. Similar objectives were also established in
the Finnish Acute Heart Failure Study (FINN-AKVA) [5], as well
as in the Czech Republic’s Acute Heart Failure Database
(AHEAD) registry [6]. The latter database was established to
monitor the diagnosis and treatment of AHF patients hospi-
talized in the Czech Republic. The project was initiated in 2005
at the Internal Cardiology Department of University Hospital
Brno (AHEAD Core; Brno, Czech Republic) as part of a research
project. The project continued in 2006 as a prospective
database called ‘AHEAD Main’ and was operational in five
large healthcare facilities with onsite Angiography Units
(General Teaching Hospital in Prague, IKEM Prague, St Anne’s
Teaching Hospital, University Hospital Brno and University
Hospital Olomouc) [6]. Currently, 15 centers with 48200
records have been compiled by the project (AHEAD Network).
The treatment of heart-failure patients consumes 1–2% of the
healthcare budget in some countries (UK, The Netherlands,Sweden), two-thirds of which is spent on hospitalizations [7].
However, little is known about the structure of in-hospital costs
and variability in the financial burden among hospitalized AHF
patients according to AHF etiology. Therefore, we examined the
distribution of costs associated with AHF hospitalizations in a
Cardiology Department.2. MethodsAHEAD is a national, observational, prospective, multicentre
registry based on the etiology, treatment and prognosis of
patients hospitalized for AHF. The AHEAD Core only includes
patients from University Hospital Brno. The health/economic
sub-project initiated at University Hospital Brno only evalu-
ates the cost of the first recorded hospitalization per AHF
subject admitted during the study period, regardless of
whether or not hospitalization was due to de-novo AHF
or ADCHF.
Cost analysis was undertaken from the perspective of the
healthcare payer; neither indirect (e.g. loss of earnings) nor
intangible costs (e.g. pain and suffering) were measured. The
costs were subtracted from the hospital account of each
registered patient. The burden incurred during hospitalization
consisted of the burden of a standard Cardiology Unit (SCU) and
the burden of a Coronary Care Unit (CCU). There are 2 CCUs
with a total of 12 beds. Two doctors and four nurses take care of
6 patients at a time. Each CCU provides monitoring of ECG and
blood pressure, non-invasive and invasive pulmonary ventila-
tion, methods of continuous renal replacement therapy and
hemodynamic support including an intra-aortic balloon pump
(IABP). The total in-hospital cost included the flat rate of
admission, hospital stay and the cost of investigations and
interventions. Expenses for cardiac surgeries (coronary artery
bypass grafting, valve replacement, etc.) were not included
because the procedures were carried out in the Cardiac Surgery
Unit which is external to University Hospital. After cardiac
surgery, patients were discharged homewithout being sent back
to the previous cardiology department. The overall cost for
cardiac surgery was only determined for a portion of the
patients (2005–2007) and was described in a previous article;
some of these results are presented in the discussion. Medical
therapy provided during a hospital stay was included in the
daily in-patient rate (room rate); extra medications and extra
sanitary materials used during medical procedures were calcu-
lated separately. The costs of daily care in the CCUwere counted
according to the Therapeutic Intervention Scoring System (TISS)
score. All charges came from fixed-fee schedules in the index of
medical procedures (physicians’ services) and the code-lists of
pharmaceuticals published by the Czech Ministry of Health.
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Institute of Biostatistics and Analyses, Masaryk University
(Brno, Czech Republic). Costs were presented as the mean,
standard deviation, median, 5th and 95th percentiles. Statis-
tical significance was tested using the Fisher exact test for
two dichotomous categories and the ML w2 test for variables
with more than two categories. The (non-parametric)
Mann–Whitney U test was used for continuous data between
two groups of patients and the Kruskal Wallis test for
comparison among several groups of patients or years.
Po0.05 was considered significant. All prices were calculated
without value-added tax (VAT). The average exchange rate for
2005–2009 was h1¼27.5 CZK [8], exchange rate USD/EUR was
used from 2005—USD 1.2441¼1h.
The study protocol complied with the Declaration of
Helsinki and was approved by the local Ethics Committee of
Faculty Hospital Brno and by the Ethics Committee of
Masaryk University in Brno. An informed written consent
was obtained from all subjects before participation in
the study.2.1. Study population
A total of 1759 patients (58.7% male) hospitalized at Univer-
sity Hospital Brno with AHF between 2005 and 2009 were
enrolled. Study Physicians grouped patients according to AHF
etiology upon hospital admission (acute coronary syndrome
(ACS), chronic ischemic heart disease (CIHD), valvular dys-
function, arrhythmia, hypertensive crisis and others).Table 1 – Characteristics of the study population.
Total N
%
Sex (female) N
%
Age All (years) Mean
(SD)
r60 years N
%
61–70 years N
%
71–80 years N
%
480 years N
%
History Hypertension N
%
Diabetes mellitus N
%
Previous PCI/CABG N
%
Previous PM/ICD/CRT N
%
PCI – percutaneous coronary intervention; CABG – coronary artery bypas
CRT – cardiac resynchronization therapy with biventricular device; ADC3. Results
The baseline characteristics of patients upon hospital admis-
sion, and their distribution by AHF type, are shown in Table 1.
Acute decompensation of chronic heart failure was found in
39.2% of patients; others were diagnosed as de-novo AHF.
Males suffered from CIHD and ACS more often than females
(68% vs. 62%), whereas more females (69%) were admitted
with hypertensive crisis as the cause of AHF.
The mean cost of hospitalization due to AHF was h3364 (CZK
92,515). The median length of stay (LOS) was 7 days. Two-thirds
of the study group was treated in the CCU and their median
LOS in the CCU was 3 days. Significantly higher costs were
found in patients with new-onset AHF (mean h3678; CZK
101,139) compared to ADCHF patients (h2878; CZK 79,154;
po0.001). The difference was mainly caused by a greater need
for CCU care, a longer stay in the CCU and a greater number of
interventions (particularly PCI) in patients with new-onset AHF.
ACS was the major causal factor for hospitalization due to
AHF (present in 44.5% of patients) and the total cost was three
times higher than that of valvular dysfunction and hyperten-
sive crisis, and one-third higher than in patients with CIHD or
other precipitating factors. More ACS patients needed treat-
ment in the CCU compared to other clinical classes (twice as
many as patients with CIHD, valvular dysfunction, arrhyth-
mias), but the length of stay in the CCUwas, on average, shorter
(Table 2). Variations in total LOS for patients with different
causes of AHF were small (median, 6–8 days) (Table 3).
Coronary angiography was carried out during the course of
hospitalization or recently performed in 64.0% of patients.All Type of heart failure
De-novo AHF ADCHF p
1759 1062 690 –
100% 60.8% 39.2%
727 458 269 0.113
41.3% 42.8% 39.0%
70.9 69.8 72.5 o0.001
(12.2) (12.5) (11.5)
324 236 88 o0.001
18.4% 22.1% 12.8%
401 246 155 0.816
22.8% 23.0% 22.5%
614 353 261 0.041
34.9% 33.0% 37.8%
420 234 186 0.016
23.9% 21.9% 27.0%
1217 694 523 o0.001
71.0% 67.5% 76.1%
711 385 326 o0.001
41.3% 37.3% 47.4%
198 47 151 o0.001
13.5% 4.4% 21.9%
232 69 163 o0.001
11.3% 6.7% 23.7%
s graft; PM – pacemaker; ICD – implantable cardioverter-defibrillator;
HF – acute decompensation of chronic heart failure.
Table 2 – Structure of in-hospital costs (h) according to type and etiology of AHF.
N / % 
 latoT cimhtyhrra-itnA GAC ICP UCS + UCC
Mean 
(SD) Median 0.05 0.95 
Mean 
(SD) Median 0.05 0.95 
Mean 
(SD) Median 0.05 0.95
Mean 
(SD) Median 0.05 0.95 
Mean 
(SD) Median 0.05 0.95 
All patients 1759 / 100 1217 (1714) 729 208 4294
4086
(1729) 3621 2287 7878
479
(132) 466 298 712
14309 
(16182) 4983 1595 40543
3364
(5928) 1383 236 9502
Type of 
AHF 
De-novo 
AHF 1069 / 60.8 
1337 
(1670) 815 243 4734
4037
(1680) 3589 2286 7812
469
(123) 454 298 676
11530 
(14459) 4460 1601 40995
3678
(4810) 2670 309 9598
ADCHF 690 / 39.2 1031(1767) 553 188 3136
4415
(2014) 3831 2188 9028
498
(146) 474 298 751
16531 
(17247) 6570 1566 41211
2878
(7307) 758 199 8770
p <0.001    0.146    0.027      0.169    <0.001    
Aetiology 
ACS 782 / 44.5 1458(1701) 884 277 5181
4060
(1696) 3589 2287 7823
462
(118) 451 297 682
12319 
(16749) 2068 544 44938
4429
(4589) 3916 560 10097
CIHD 329 / 18.7 965(2003) 525 199 3056
4856
(2162) 4251 2399 10484
509
(170) 472 300 993
17104 
(16169) 7043 1596 40985
2827
(7502) 649 203 9274
Valvular  
disorder 140 / 8.0 
1050
(2016) 519 179 3417
4287
(2523) 3857 2289 9616
516
(148) 477 343 748
3060
(3105) 1939 672 6570
1489
(2430) 697 179 4839
Arrhythmia 97 / 5.5 983(1056) 641 180 3520
4134
(-) 4134 4134 4134
496
(187) 454 286 987
14009 
(14834) 5489 1611 37694
3991
(9276) 742 180 34231
Hypertensive  
crisis 91 / 5.2 
844
(826) 626 198 2842  -- -- -- -- 
452
(151) 454 286 766
14068 
(16922) 4491 4107 33607
1371
(3994) 702 229 3990
Other 320 / 18.2 1133(1552) 627 188 3450
3591
(1684) 3405 1575 7796
475
(90) 474 319 619
14309 
(18007) 4613 1507 58258
2512
(6682) 877 207 8073
p <0.001    0.303    0.022      0.435    <0.001    
CCU – Coronary care unit stay; SCU – standard cardiology unit stay; PCI – percutaneous coronary intervention; CAG – coronary angiography; ADCHF – acute decompensation of chronic heart failure;
ACS – acute coronary syndrome; CIHD – chronic ischemic heart disease. nnCosts presented as Euro: mean (SD), median, 5th and 95th percentiles.
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Table 3 – Length of stay, interventions and mortality.
Total
In-hospital stay Intervention
Mortality
CCU need CCU daysa Total LOSb PCI CAG Anti-Arrhythmic
All patients
N 1759 1186 2.6 (3.7) 8.1 (5.9) 534 1125 99 263
% 100% 67.4% 2.0 (0.0; 9.0) 7.0 (1.0; 19.0) 30.4% 64.0% 5.6% 15.0%
Type of AHF
De-novo
N 1069 838 2.9 (3.7) 7.9 (5.8) 466 744 44 170
% 60.8% 78.4% 2.0 (0.0; 9.0) 7.0 (1.0; 18.0) 43.6% 69.6% 4.1% 15.9%
ADCHF
N 690 348 2.0 (3.6) 8.5 (6.1) 68 381 55 93
% 39.2% 50.4% 1.0 (0.0; 8.0) 7.0 (1.0; 20.0) 9.9% 55.2% 8.0% 13.5%
p o0.001 o0.001 0.026 o0.001 o0.001 0.001 0.171
Etiology
ACS
N 782 717 3.3 (3.5) 7.3 (5.7) 495 687 19 144
% 44.5% 91.7% 2.0 (0.0; 9.9) 6.0 (1.0; 18.0) 63.3% 87.9% 2.4% 18.4%
CIHD
N 329 148 1.8 (3.5) 8.7 (5.3) 21 189 28 35
% 18.7% 45.0% 0.0 (0.0; 8.0) 8.0 (1.0; 18.0) 6.4% 57.4% 8.5% 10.6%
Valvular disorder
N 140 57 2.3 (5.5) 10.0 (8.1) 7 67 3 16
% 8.0% 40.7% 0.0 (0.0;11.0) 8.0 (1.0; 26.0) 5.0% 47.9% 2.1% 11.4%
Arrhythmia
N 97 38 1.6 (3.0) 9.3 (5.4) 1 20 20 4
% 5.5% 39.2% 0.0 (0.0; 8.1) 8.0 (2.0; 22.2) 1.0% 20.6% 20.6% 4.1%
Hypertensive crisis
N 91 57 2.1 (3.1) 7.7 (5.9) 0 23 3 5
% 5.2% 62.6% 1.0 (0.0; 6.4) 6.0 (1.0; 18.5) 0 25.3% 3.3% 5.5%
Other
N 320 169 2.2 (3.2) 8.5 (5.8) 10 139 26 58
% 18.2% 52.8% 1.0 (0.0; 9.0) 7.0 (1.0; 19.1) 3.1% 43.4% 8.2% 18.2%
p o0.001 o0.001 o0.001 o0.001 o0.001 o0.001 o0.001
LOS – length of stay; CCU – coronary care unit; PCI – percutaneous coronary intervention; CAG – coronary angiography; ADCHF – acute decompensation of chronic heart failure; ACS – acute coronary
syndrome; CIHD – chronic ischemic heart disease.
a CCU days counted from all patients in category; presented as mean (SD), median (5th and 95th percentiles).
b LOS presented as mean (SD), median (5th and 95th percentiles).
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Fig. 1 – Proportion of costs according to type of AHF and etiology.
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CIHD patients (57.4%). PCI revascularization was carried out
in 30.4% of patients; 43.6% in de-novo AHF and 9.9% in
ADCHF. As expected, most were performed in ACS patients
(63.3% PCI rate). The burden of anti-arrhythmic treatment
with pacemakers, implantable cardioverter-defibrillators or
cardiac resynchronization therapy was only recorded in 5.6%
of patients (8.0% in ADCHF and 4.1% in new-onset AHF). The
pacemakers were implanted in 3.2% of patients, cardioverter-
defibrillators (with or without CRT) in 1.6% of patients and
cardiac resynchronization therapy in 0.8% of patients. Hence,
their costs were not compared between subgroups.
The mean cost per day was h370.2 (CZK 10,179) in the CCU
and h51.6 (CZK 1420) in the Standard Cardiology Unit (SCU).
The mean cost per intervention (including the device) was
h4086 (CZK 112,353) for PCI revascularization and h14,309 (CZK
393,486) when treatment involved arrhythmia treatment via
pacemaker implantation, implantable cardioverter-defibrillator
or cardiac resynchronization therapy with a biventricular
device.
The structure of total in-hospital costs varied according to
the type of AHF and etiology. Concerning results for all
patients, the most expensive factors were revascularization
procedures and cardiac catheterizations. These contributed
to 40% of total in-patient costs. The stay in the CCU repre-
sented 28% of total in-patient costs and anti-arrhythmic
interventions comprised 24%. In patients for whom valvular
dysfunction or hypertensive crisis led to AHF hospitalization,
the room rate equaled about two-thirds of the total cost
(mainly due related to the CCU stay) (Fig. 1).
Overall in-hospital mortality was 15.0%. No relationship
between mortality rate of ADCHF and de-novo AHF was
observed. However, a significant difference in mortality rate
was observed among AHF etiologies (Table 3).
No statistically significant annual growth in mean cost per
patient was observed between the years 2005–2008 (h3482;
3090; 3261 and 3674, respectively; p¼0.119). Because a limited
number of hospitalization records were evaluated in 2009,
this year was not included in trend analysis.4. Discussion
The present study confirmed that AHF patients should not be
regarded as a single, ‘‘uniform’’ population, but grouped
according to AHF type or precipitating factors which led to
hospitalization. There were significant differences during the
course of hospitalizations and their outcomes. In our patients,
de-novo AHF was more common than ADCHF, which is not in
accordance with international data [2,4,5,9]. However, concor-
dant to other studies [2,5,10], the most frequent precipitating
factor was the presence of ACS. The main cause of a larger
number of patients with de-novo AHF is probably the centra-
lization of care for patients with ACS and other severe cardiac
diseases in the Czech Republic. Patients with de-novo AHF
often undergo examinations including coronary angiography
in a specialized center, while patients with ADCHF are hospi-
talized in a regional hospital. The Department of Internal
Cardiology Medicine, University Hospital Brno, is a specialized
cardiology center; its catchment area includes 500,000 poten-
tial cardiac patients while the general internal medicine area
covers just 20,000 people to be treated in this center. Patients
with de-novo AHF were younger, and with fewer co-morbid-
ities, than those with ADCHF. Despite the fact that new-onset
AHF patients incurred higher costs than ADCHF patients; a
better predictor of a longer in-hospital stays was ADCHF.
Among all patients, ACS patients incurred the highest costs;
92% of ACS patients required a CCU stay, but had a shorter
LOS. We identified the primary drivers of increased costs in all
patients hospitalized with AHF: undergoing PCI and a stay in
the CCU. The proportion of costs (CCU, SCU, CAG, PCI, and
anti-arrhythmic interventions) varied between subgroups and
confirmed that in-patient care for AHF patients was hetero-
geneous with respect to resources used. In patients with
hypertensive crisis and arrhythmias as the precipitating
causes of AHF, cost and outcome must be interpreted with
caution, given the small number of patients evaluated.
Admission for AHF is a high-risk event, particularly for
patients with ACS. Overall in-hospital mortality in the study
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 7 – e 1 4 e13population was 15%, which was higher than in comparable
AHF studies. In previous studies, increased risk of in-hospital
mortality in AHF patients was related to myocardial infarc-
tion, cardiogenic shock, worsening of renal function, higher
age, tachycardia, increased level of natriuretic peptides,
hyponatremia, hypotension and left-ventricular systolic dys-
function [11–15].
Healthcare expenditures in the Czech Republic are still very
low compared to Western countries. AHF hospitalization
incurred a mean cost of h3364 with a mean LOS of 8.1 days.
A comparison with previously published studies involving
the utilization of resources in AHF hospitalizations would
be misleading because most of the data are only based on the
in-patient cost of treating subjects with heart failure, without
AHF etiology differentiation. Furthermore, in many coding sys-
tems, AHF caused by ACS could be coded as a myocardial
infarction and not AHF. Moreover, the strategies for evaluating
these expenditures in published sources might have been
different. The costs associated with acute hospitalization and
subsequent rehabilitation among different classes of AHF was
evaluated in the FINN-AKVA study population in Finland [5]. The
cost of the index hospitalization was calculated based upon the
number of days in the Intensive Cardiology Unit (ICU; h1576/day),
CCU (h970/day) and the cost of a stay on a conventional ward
(h340/day). The mean length of index hospitalization was 9.2
days. The mean cost per index hospitalization was h6743, based
solely on room rates per day [16], which was double that of our
analysis, which also included interventions and devices. The
mean cost per hospitalization for heart failure in the USA in 2005
varied according to the inotropic therapy used. The mean length
of stay for patients initiated on a single vasodilator or inotrope
was 6.7 days and 9.6 days, respectively and the cost was $12,038
and $18,411, respectively (h9676 and h14,799). In patients receiv-
ing Z2 vasoactive drugs during hospitalization, the total mean
cost ranged from $14,790 to $46,479 (h11,888 and h37,360);
patients receiving only intravenous inotropes, or in combination
with other therapies, had consistently higher mortality and
costs. We suppose that costs in this study, in comparison with
our data, were slightly undervalued because hospitalizations
accompanied by a device procedure (e.g. implantable
cardioverter-defibrillator on day 1 and percutaneous intervention
within the first 2 days) were excluded [17,18]. In a retrospective
cost analysis of patients hospitalized for acute decompensation
of chronic heart failure while enrolled in the Randomized
Evaluation of Intravenous Levosimendan Efficacy (REVIVE II)
study, the average stay in a hospital network in the USA lasted
8.96 days with the average cost of $19,021 (h15,289) when
standard therapy was provided [18,19].
Cardiac surgery was required in 5.7% of patients who were
hospitalized in the Cardiology Department due to AHF. Surgery
carried out after an AHF episode might be immediate or
delayed. All cardiac surgeries were undertaken at the specia-
lized Department of Cardiac and Transplant Surgery, Brno, and
not at University Hospital, Brno. In our previous article, we
evaluated the cost of cardiac surgical procedures (including
CABGs, as well as valve replacements) in a population of 63
patients with AHF [20]. The mean cost per stay in a Cardiac
Surgery Unit was CZK 310,781 (h11,301) and represented as
much as 86% of the total in-hospital costs of these patients. If
we added the mean cost per stay in the Cardiac Surgery Unit,to all 100 patients in the present study who had also under-
gone immediate CABG, the mean cost of hospitalization due to
AHF would increase to h4007 (CZK 110,183; a 19% increase).
Because the data about cardiac surgery costs were already
published, we discussed the major results in this section.
Our results may be helpful in estimating future resource
requirements. At the same time, the work shows doctors
potential cost AHF treatment.
4.1. Study limitations
The presented data are from one hospital with CathLab
service. This could lead to a slightly higher contribution of
patients with de-novo AHF, ACS and a higher percentage of
patients with coronary angiography and PCI performed dur-
ing hospitalization, possibly resulting in an overestimation of
the average cost per hospitalization.
The number and cost of anti-arrhythmic interventions may
have been partly underestimated because some patients,
particularly those with ACS, were electively readmitted for
device implantation. According to the guidelines of the Eur-
opean Society of Cardiology, prophylactic implantation of ICD
to reduce the risk of sudden death in patients with left
ventricle dysfunction is indicated no less than 40 days after
myocardial infarction. In our work, we only evaluated the first
hospitalization of each patient and, moreover, such a ther-
apeutic approach might be considered as treating a stable
patient with chronic heart failure. Finally, the long-term
monitoring of all such costs was beyond our capabilities.
When comparing cost results to studies in other countries,
without knowing the background of the centers in which the
studies were completed, the assessment is only approximate.
For example, different health services treat patients with the
same diagnosis in different ways. There are several techniques
to compare the costs between countries. We decided to use the
annual mean exchange rates to make the data easier to
understand. Certain economic methods which reflect differ-
ences in price levels between countries are available for
currency conversion, i.e. based on purchasing-power parity.
Moreover, when comparing our data to studies from the United
States or Finland, we did not adjust costs for inflation from
different years, even for time preference. However, we do not
expect our original results to be utilized for foreign pharmaco-
economic studies, because economic data cannot be easily
transferred from one setting to another (e.g. availability of
treatments, patterns of clinical practice, relative prices) [21–24].5. Conclusions
Hospitalization costs related to AHF were high (particularly in
new-onset AHF patients). The median hospital stay was 7 days
and in-patient costs averaged h3364 (including all interventions)
in all AHF patients. The heterogeneity of resource use was
largely a reflection of interventions undertaken (particularly if
revascularization or anti-arrhythmic therapy was provided). The
room rate reflected only 36% of total costs in AHF patients (28%
of the total cost was related to the CCU stay).
The most important finding was that hospitalization costs
of patients admitted with AHF vary tremendously among
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 7 – e 1 4e14different AHF etiologies. There were significant differences in
CCU need, LOS, SCU costs, total CCUþSCU costs, total in-
hospital costs (including interventions) and mortality rates.
Among all patients, ACS patients incurred the greatest costs,
because PCI was carried out in almost two-thirds of these
patients and a CCU stay was required for 490% of them.
The major limitation of this work was that only direct costs
of cardiology department hospitalizations for the acute phase
of heart failure were evaluated, and no long-term monitoring
of subsequent costs was carried out.Competing interests
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